NASDAQ · Health Care

NOVAVAX INC NVAX

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.

Biotechnology: Biological Products (No Diagnostic Substances)

Company profile

Business mix

  • The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
  • The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within biotechnology?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 1 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE N/A FCF -6.2% Buyback -0.58%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Coatue Management Philippe Laffont 0.1% $31.2M 2026-03-31

Recent trading changes over the last 1 quarters

Net buyers 1 Last 1 13F filing periods
Net reducers 0 Last 1 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $31.2M Estimated from net added shares
Reduction amount $0 Estimated from net reduced shares
Net share change / base shares New +3,836,986 / 0
Coatue Management Philippe Laffont 1 filing periods
13F 2026-03-31 Filed 2026-05-15
New Shares - 13F value change +$31.2M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 1 periods +3,836,986 (New) Total shares 3,836,986 Value $31.2M

Recent mentions

No public mentions.